Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?

by Alexander Chehrazi-Raffle, Sumanta Kumar Pal
Published 2020-06-01

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

by Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia
Published 2018-01-01

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma

by Alexander Chehrazi-Raffle, Tanya B. Dorff, Sumanta K. Pal, Yung Lyou
Published 2021-02-01

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies

by Jun Gong, Alexander Chehrazi-Raffle, Veronica Placencio-Hickok, Michelle Guan, Andrew Hendifar, Ravi Salgia
Published 2019-03-01

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California

by Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Published 2021-08-01